SCHEMBL14815323

SCHEMBL14815323

O=C(O)N1CC[C@@H]2CC[C@@H](Nc3cccc(C(F)(F)F)n3)N2C1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HCRTR2 O43614 2/20 0.43
▸ HCRTR1 O43613 2/20 0.43
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ HSD11B1 P28845 1/20 0.40
▸ TAS2R14 Q9NYV8 1/20 0.39
▸ BTK Q06187 1/20 0.39
▸ IDH1 O75874 4/20 0.37
▸ IDH2 P48735 6/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.35
▸ KCNH2 Q12809 2/20 0.35
▸ SYK P43405 1/20 0.35
▸ HTR1A P08908 1/20 0.34
▸ DRD2 P14416 1/20 0.34
▸ DRD4 P21917 1/20 0.34
▸ IRAK4 Q9NWZ3 2/20 0.34
▸ JAK2 O60674 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14815100 0.88 HCRTR2 (0.41) HCRTR2HCRTR1CYP3A4CYP2D6CYP2C9
SCHEMBL14815301 0.86 EPHX2 (0.41) HCRTR2HCRTR1
SCHEMBL14815213 0.85 HCRTR2 (0.41) HCRTR2HCRTR1CYP3A4CYP2D6CYP2C9
SCHEMBL14815318 0.85 HCRTR2 (0.38) HCRTR2HCRTR1CYP3A4CYP2D6CYP2C9
SCHEMBL14815290 0.82 HCRTR1 (0.42) HCRTR2HCRTR1HSD11B1TAS2R14SYK
SCHEMBL14815518 0.81 PHGDH (0.41) HCRTR2HCRTR1IDH2HRH3DRD2
SCHEMBL14815306 0.80 EPHX2 (0.43) HCRTR2HCRTR1CYP3A4CYP2D6CYP2C9
SCHEMBL14814728 0.77 HCRTR2 (0.39) HCRTR2HCRTR1BTKIDH1IDH2
SCHEMBL14815443 0.77 HCRTR2 (0.40) HCRTR2HCRTR1CYP3A4CYP2D6CYP2C9
SCHEMBL14815064 0.74 HRH1 (0.45) DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130085142-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-04-04 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085142-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS CACNA1C, CACNA1E, CACNA1D HCRTR2 434/4885HCRTR1 654/4885CYP3A4 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback